Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts [Yahoo! Finance]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Yahoo! Finance
TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating. The firm noted that 2026 will be a key year for bexobrutideg as management progresses two registrational trials and provides additional Phase 1 updates. In contrast, on the same day, Wells Fargo lowered the price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $29 from $30 and maintained an Overweight rating. The firm points out that even in the absence of clinical triggers in 2026, the shares are still cheap and could increase in the second half of the year before significant catalysts in 2027. Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company that develops targeted protein modulation therapies using its proprietary DELigase platform. NRIX focuses on ubiquitin signaling pathways in order to develop degraders and small-molecule programs for immunology and oncology illnesses and develops precision medicines to address unmet medical needs an
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) was given a new $35.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Nurix Therapeutics (NASDAQ:NRIX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
NRIX
Earnings
- 1/28/26 - Beat
NRIX
Sec Filings
- 2/3/26 - Form 4
- 1/30/26 - Form 4
- 1/30/26 - Form 4
- NRIX's page on the SEC website